Brimonidine tartrate 0.1% eyedrops new and effective treatment of rosacea
Keywords:
Rosacea, brimonidine tartarateAbstract
Objective To determine the efficacy of brimonidine tartrate eye drops for treatment of erythema associated with rosacea. Methods Fifty patients with rosacea (41 females and 9 males, mean age 35 years) were randomized to receive once daily single application of BT or vehicle for 4 weeks. Evaluation at 8 weeks included clinician’s erythema assessment (CEA), patient’s self-assessments (PSA) and photographic documentation. Results Based on CEA and PSA, clinical response of 96.5% was seen with BT eyedrops as compared to 20.8% with placebo (p<0.05). Increased burning sensation and dermatitis was seen with BT in 2 (8.7%) patients, while rebound erythema occurred in 1 (4.3%) after BT use. Conclusion Single daily application of BT eye drops provides significantly greater efficacy than vehicle for treatment of moderate to severe erythema of rosacea.References
Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-41.
Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol. 2005;19:273-85.
Aksoy B, Altaykan-Hapa A, Egemen D et al. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163:719-25.
Schwab V, Sulk M, Seeliger S et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:53-62.
Odom R, Dahl M, Dover J et al. Standard management options for rosacea. Part I: overview and broad spectrum of care. Cutis. 2009;84:43-7.
Odom R, Dahl M, Dover J et al. Standard management options for rosacea. Part II: option according to subtype. Cutis. 2009;84:97-104.
Chang BP, Kurian A, Barankin B. Rosacea: an update on medical therapies. Skin Therapy Lett. 2014;19(3):1-4.
Rahman MQ, Ramaesh K, Montgomery DNI. Brimonidine for glaucoma. Expert Opin Drug Saf. 2010;9:483-91.
Abramovits W, Prato A, Vincent KD et al. MIRVASO (brimonidine tartrate) topical gel 0.33%. Skinmed. 2014;12:41-3.
Fowler J Jr, Jackson M, Moore A et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12:650-6.
Fowler J, Jarratt M, Moore A et al. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166:633-41
Jackson JM, Fowler J, Moore A et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. J Drugs Dermatol. 2014;13:699-704.
Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective 1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143:1369-71.
Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol. 1989;20:202-5.
Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol. 2005;53:881-4.
Piwnica D, Rosignoli C, de Ménonville ST. Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci. 2014;75:49-54.
Routt ET, Levitt JO. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. J Am Acad Dermatol. 2014;70:e37-8.
Swanson LA, Warshaw EM. Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea. J Am Acad Dermatol. 2014;71:832-3.
Moore A, Kempers S, Murakawa G et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13:56-61.
